A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer
Tekijät: Tüzmen Şükrü, Hostetter Galen, Watanabe Aprill, Ekmekçi Cumhur, Carrigan Patricia E, Shechter Ishaiahu, Kallioniemi Olli, Miller Laurence J, Mousses Spyro
Kustantaja: Future Medicine Ltd
Julkaisuvuosi: 2019
Journal: Personalized Medicine
Tietokannassa oleva lehden nimi: PERSONALIZED MEDICINE
Lehden akronyymi: PERS MED
Vuosikerta: 16
Numero: 1
Aloitussivu: 51
Lopetussivu: 65
Sivujen määrä: 15
ISSN: 1741-0541
eISSN: 1744-828X
DOI: https://doi.org/10.2217/pme-2016-0058
Tiivistelmä
Aim:To help characterize theFDFT1 gene and protein expression in cancer.Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.
Aim:To help characterize theFDFT1 gene and protein expression in cancer.Cholesterol represents an important structural component of lipid rafts. These specializations can be involved in pathways stimulating cell growth, survival and other processes active in cancer. This cellular compartment can be expanded by acquisition of cholesterol from the circulation or by its synthesis in a metabolic pathway regulated by the FDFT1 enzyme. Given the critical role this might play in carcinogenesis and in the behavior of cancers, we have examined the level of this enzyme in various types of human cancer. Our demonstration of elevated levels of FDFT1 mRNA and protein in some tumors relative to surrounding normal tissue identifies this as a possible biomarker for disease development and progression, and as a potential new target for the treatment of cancer.
Turun yliopiston Tutkimustietojärjestelmän portaali